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ABSTRACT
Objective: Analyze patients with HIV infection from Curitiba, Paraná, their epidemiological 
characteristics and HIV RAM. Methods: Patients regularly followed in an ID Clinic had their 
medical data evaluated and cases of virological failure were analyzed with genotypic report. Re-
sults: Patients with complete medical charts were selected (n = 191). Demographic and clinical 
characteristics were compared. One hundred thirty two patients presented with subtype B infec-
tion (69.1%), 41 subtype C (21.5%), 10 subtype F (5.2%), 7 BF (3.7%) and 1 CF (0.5%). Patients 
with subtype B infection had been diagnosed earlier than patients with subtype non-B. Also, 
subtype B infection was more frequent in men who have sex with men, while non-B subtypes 
occurred more frequently in heterosexuals and women. Patients with previous history of three 
classes of ARVs (n = 161) intake were selected to evaluate resistance. For RT inhibitors, 41L 
and 210W were more frequently observed in subtype B than in non-B strains. No differences 
between subtypes and mutations were observed to NNTRIs. Mutations at 10, 32 and 63 position 
of protease were more observed in subtype B viruses than non-B, while positions 20 and 36 of 
showed more amino acid substitutions in subtype non-B viruses. Patients with history of NFV 
intake were evaluated to resistance pathway. The 90M pathway was more frequent in subtypes B 
and non-B. Mutations previously reported as common in non-B viruses, such as 65R and 106M, 
were uncommon in our study. Mutations 63P and 36I, previously reported as common in HIV-1 
subtypes B and C from Brazil, respectively, were common. Conclusion: There is a significant 
frequency of HIV-1 non-B infections in Paraná state, with isolates classified as subtypes C, F, BF 
and BC. Patients with subtype C infection were more frequently female, heterosexual and had a 
longer average time of HIV diagnosis.
Keywords: HIV, aids, subtypes, subtype B, subtype non-B, genetic diversity, antiretroviral, Brazil.
[Braz J Infect Dis 2010;14(5):495-501]©Elsevier Editora Ltda.
INTRODUCTION
It is unresolved whether the extent that HIV-1 
genetic diversity has impacts in the outcome 
of its treatment or its biological behavior. 
At least 9 subtypes, 5 sub-subtypes and 34 
circulating recombinant forms (CRFs) have 
been reported worldwide.1 Most knowledge 
about HIV is related to HIV-1 subtype B, 
but 90% of HIV-1 infection in the globe is 
caused by HIV-1 subtype non-B.2
Brazil has the greatest number of HIV-
infected patients in South America.3 The 
HIV subtype that predominates is B, but in-
creased detection of others subtypes, mainly 
F in northern and C in southern part of the 
country, has been described.4,5,6 Also, Bra-
zil has provided free access to antiretroviral 
(ARV) medications for all HIV infected 
patients since 1996, providing a good set-
ting to study the impact of HIV diversity 
on resistance mutation patterns.7 Paraná 
is a state localized in south Brazil and very 
scarce data have been published about its 
HIV-1 subtype prevalence. In this report, 
we analyze patients with HIV-1 infection 
from Paraná and discuss their epidemio-
logical characteristics and RAM.
METHODS
Patients regularly followed in an Infectious 
Diseases Clinic in Curitiba, Paraná, par-
ticipated in this study. Two hundred eleven 
patients were initially enrolled. Inclusion 
criteria were age above 18 years, HIV-1 
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infection, available laboratory and ARV treatment history 
and genotype report with subtype. The genotype methods 
were VircoType HIV-1® and Phenosense GT® and a region 
pool was analyzed. Clade assignment was restricted to re-
gion analyzed and was described as reported by resistance 
test. Patients with previous history of intake and virological 
failure to 3 ARV class were also evaluated by resistance pro-
fi le according to different subtype. Main mutations of each 
class were compared in different subtypes. Statistical analy-
sis was used to verify for signifi cant differences between de-
mographic and clinical profi les and frequencies of RAMs in 
different subtypes. Multivariate analysis was used to evaluate 
the effect of characteristics with a p value of less than 0.25 
in the univariate analysis. Logistic regression was used, con-
sidering Wald test to analyze the level of signifi cance. RAMs 
were selected according to recent literature.8 This study was 
approved by the Internal Review Board Comitê de Ética do 
Hospital de Clínicas da Universidade Federal do Paraná.
RESULTS
From 1987 to 2008, 211 patients had specimens submitted 
for resistance tests because of virological failure, and 191 
met all inclusion criteria (Table 1).
Patients were diagnosed with HIV infection between 
1987 and 2008, presenting from 20 to 72 years old. One 
hundred forty patients were male and 51 females.
Patients with subtype non-B were more frequently 
female (45.8% vs 18.2%, p < 0.001) and reported more 
commonly heterosexual exposure as their single HIV 
risk for infection than patients with subtype B infec-
tion (78% vs 47.7%, p < 0.001). The average duration of 
HIV-1 diagnosis was longer in patients with subtype B 
than subtype non-B (p = 0.005) (Table 2).
Age, gender, risk factor for HIV infection (MSM ver-
sus heterosexual) and average time of diagnosis were ana-
lyzed in a multivariate model and is showed in Table 3.
We observed that in non-adjusted (univariate) and 
in adjusted (multivariate) analyses, the associations 
involving female sex, heterosexual practice and longer 
time of HIV diagnosis reached statistical significance 
and were independently related to HIV subtype non-B 
infection.
There were no other significant differences in clinical 
or demographic characteristics among subtypes.
From 191 patients, 115 had a previous history of 
treatment with all of the original antiretroviral classes 
and virological failure.
NRTI resistance mutations
There was no statistical difference between mutations 
comparing subtype B and non-B (Table 5). Mutation 
V106A/M was found in only 1 patient with subtype B 
and 1 subtype C.
Table 1. Shows patients demographic and clinical profiles
    Subtype
  B C F BF CF
  (n = 132) (n = 41) (n = 10) (n = 7) (n = 1)
Age yr±SD 42.0 ± 9.7 40.6 ± 8.7 43.2 ± 8.4 36.9 ± 8.1 24
Sex (%) Male 108 (81.8) 24 (58.5) 4 (40.0) 4 (57.1) 0
 Female 24 (18.2) 17 (41.5) 6(60.0) 3 (42.9) 1
HIV-1 risk factor (%) MSM 68 (51.5) 9 (22) 2 (20.0) 1 (14.3) 0
 Heterosexual 63 (47.7) 31 (75.6) 8 (80.0) 6 (85.7) 1 (100)
 IVDU 0 1 (2.4) 0 0 0
 Congenital 1 (0.8) 0 0 0 0
Race (%) Caucasian 118 (89.4) 38 (92.7) 10 (100) 7 (100) 1 (100)
 Black 14 (10.6) 3 (7.3) 0 0 0
CDC Clinical Stage (%) A 60 (45.4) 23 (56.2) 6 (60.0) 1 (14.3) 1 (100)
 B 31 (23.5) 9 (21.9) 2 (20.0) 2 (28.6) 0
 C 41 (31.1) 9 (21.9) 2 (20.0) 4 (57.1) 0
Average time of diagnosis yr ± SD 9.0  ± 5.0 7.0 ± 3.8 8,0 ± 4,0 7.1 ± 3.4 4.0
CD4 (cels/mm3) Average ± SD 222 ± 134 237 ± 130 263 ± 133 236 ± 163 498
Viral load (copies/mL) Average ± SD 99,700 ±  114,853 ± 132,536 ± 59,165 ±
  210,344 224,916  238,279 97,861 
782
HIV subtype, epidemiological and mutational correlations in patients from Paraná, Brazil
497Braz J Infect Dis 2010; 14(5):495-501
Table 3. Multivariate analysis of multiple factors and infection by subtype B and non-B
 p OR 95% CI
Age 0.601 1.01 0.97 1.05
Gender 0.023 2.55 1.13 5.75
Risk factor for HIV infection 
(MSM or heterosexual) 0.023 2.65 1.14 6.15
Avarage time of diagnosis 0.019 0.91 0.83 0.98
Table 2. Demographic and clinical characteristics of HIV-1-positive patients infected with subtype B and non-B
  Subtype  
p
  B  non-B (B vs non-B)
  (n = 132) (n = 59) 
Age yr ± SD 42.0 ± 9.7 41.0 ± 8.5 0.480a
Sex (%) Male 108 (81.8) 32 (54.2) 
 Female 24 (18.2) 27 (45.8) < 0.001c
HIV-1 risk factor (%) MSM 68 (51.5) 12 (20.3) 
 Heterosexual 63 (47.7) 46 (78.0) < 0.001c*
 IVDU 0 1 (1.7) 
 Congenital 1 (0.8) 0 
Race (%) Caucasian 118 (89.4) 56 (94.9) 
 Black 14 (10.6) 3 (5.1) 0.278c
CDC Clinical Stage (%) A 60 (45.4) 31 (52.5) 
 B 31 (23.5) 13 (22.0) 
 C 41 (31.1) 15 (25.4) 0.635b
Average time of diagnosis yr ± SD 9.0 ± 5.0 7.1 ± 3.8 0.005a
CD4 (cels/mm3) average ± SD 222 ± 134 225 ± 120 0.458a
Viral load (copies/mL) average ± SD 99,700 ± 210,344 114,853 ± 224,916 0.653a
Average time of ARV treatment yr ± SD 6.59 ± 2.83 (n = 115) 6.16 ± 3.10 (n = 45) 0.395a
a Student’s t-test, p < 0.05; b Qui-square test, p < 0.05; c Fischer’s exact test , p < 0.05; *  MSM vs Heterosexual.
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Table 4. Mutations for NRTIs and their frequency in patients with HIV-1 B and non-B
Mutation B% Non-B% 
 (n = 115) (n = 45) 
p*
41L 59 (51.3) 13 (28.9) 0.013
62V 9 (7.8) 2 (4.4) 0.729
65N/R 2 (1.7) 0 (0) 1
67N 47 (40.9) 16 (35.6) 0.592
69ins 1 (0.9) 0 (0) 1
70R 25 (21.7) 14 (31.1) 0.225
74V/I 14 (12.2) 6 (13.3) 0.796
75T/M/I 11 (9.6) 5 (11.1) 0.773
77L 3 (2.6) 0 (0) 0.560
116Y 1 (0.9) 2 (4.4) 0.191
151M 2 (1.7) 2 (4.4) 0.314
184V 87 (75.7) 29 (64.4) 0.171
210W 39 (33.9) 7 (15.6) 0.021
215Y/F 72 (62.6) 22 (48.9) 0.153
219Q/E 25 (21.7) 14 (31.1) 0.225
* Fisher’s exact test, p < 0.05.
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Figure 1 shows the frequency of NRTIs mutations in 
subtype B and non-B. The mutation 184V was more fre-
quently seen in subtype B than in non-B viruses. Positions 
41 and 210 of reverse transcriptase were more frequent-
ly mutated (41L and 210W) in subtype B than subtype 
non-B (51.3% vs 28.9%, p = 0.13; 33.9% vs 15.6%, p = 
0.021). 65R was rarely seen, even in subtype C, being 
found in only two patients, both with subtype B infec-
tion. Tables 4 and 5 show the frequency of NRTIs and 
NNRTIs mutations for subtype B and non-B.
Figure 1: HIV-1 subtype frequency.
Figure 2: Mutations for NRTIs and their frequency in 
patients with HIV B and non-B.
PI mutations
Major and minor mutations were analyzed and the positions 
20 (64.4% vs 35.7%, p = 0.001) and 36 (86.7% vs 50.4%, p < 
0.001) were more commonly mutated in patients with subtype 
non-B than B. Substitutions at positions 10 (64.3% vs 44.4%, 
p = 0.031), 32 (13.9% vs 2.2%, p = 0.042) and 63 (73.9% vs 
35.6%, p < 0.001) were more common in subtype B than non-B 
viruses. Table 6 shows RAM analyzed and their frequencies.
Patients with previous history of nelfi navir intake and vi-
rological failure (n = 81 patients, 61 subtype B, 20 subtype 
C and 11 subtype F) were studied regarding NFV resistance 
pathway (Figure 2). All patients that used NFV had used other 
PIs in a subsequent ARV regimen. The 90M mutation path-
way was more frequent for all subtypes, occurring in 78.7% of 
subtype B and 38.7% of non-B viruses. The pathway of mu-
tation 30N was rarely seen, with 9.8% of subtype B viruses 
presenting compared to 3.2% of non-B virus (Table 7).
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Table 5. RAMs for NNRTIs in patients infected with HIV-1 subtype B and non-B 
Mutation B% Non-B% P*
 (n=115) (n=45) (B vs non-B)
101E/P 10 (8.7) 7 (15.6) 0.254
98G 11 (9.6) 3 (6.7) 0.759
100I 5 (4.3) 1 (2.2) 1
103N/S 44 (38.3) 21 (46.7) 0.373
106A/M 1 (0.9) 1 (2.2) 0.485
108I 15 (13) 6 (13.3) 0.999
179D/E/F 5 (4.3) 0 (0) 0.323
181C/I/V 21 (18.3) 7 (15.6) 0.819
188L/H/C 6 (5.2) 2 (4.4) 1
190A/S/E 29 (25.2) 9 (20) 0.541
225H 11 (9.6) 3 (6.7) 0.759
227L/C 1 (0.9) 1 (2.2) 0.485
230L 0 (0) 1 (2.2) 0.281
236L 1 (0.9) 0 (0) 1
238N/T 9 (7.8) 2 (4.4) 0.729
* Fisher’s exact test, p < 0.05.
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Table 6. RAMs for PIs in patients infected with HIV-1 subtype B and non-B
Mutation B% Non-B%
 (n = 115) (n = 45) 
p*
58E 16 (13.9) 5 (11.1) 0.797
16E 3 (2.6) 1 (2.2) 1
60E 15 (13.0) 4 (8.9) 0.592
10I/F/V/C/R 74 (64.3) 20 (44.4) 0.031
13V 33 (28.7) 8 (17.8) 0.226
20M/R/T/I/V 41 (35.7) 29 (64.4) 0.001
23I 8 (7.0) 4 (8.9) 0.740
24I 6 (5.2) 2 (4.4) 1
30N 6 (5.2) 1 (2.2) 0.674
32I 16 (13.9) 1 (2.2) 0.042
33F 26 (22.6) 7 (15.6) 0.389
35G 0 (0) 0 (0) ---
36I/L/V 58 (50.4) 39 (86.7) < 0.001
43T 8 (7) 0 (0) 0.107
46I/L 54 (47) 14 (31.1) 0.077
47V/A 10 (8.7) 2 (4.4) 0.512
48V/M 0 (0) 0 (0) ---
50L/V 10 (8.7) 4 (8.9) 0.996
53L 13 (11.3) 2 (4.4) 0.237
54A/L/M/V/T/S 49 (42.6) 18 (40.0) 0.859
62V 24 (20.9) 7 (15.6) 0.511
63P 85 (73.9) 16 (35.6) < 0.001
64L/M/V 12 (10.4) 2 (4.4) 0.353
71V/I/T/L 58 (50.4) 17 (37.8) 0.163
73S/A/C/T 21 (18.3) 3 (6.7) 0.084
74P 3 (2.6) 2 (4.4) 0.619
76V 5 (4.3) 1 (2.2) 1
77I 31 (27.0) 6 (13.3) 0.094
82A/F/L/S/T/I 49 (42.6) 17 (37.8) 0.598
83D 1 (0.9) 0 (0) 1
84V 19 (16.5) 3 (6.7) 0.129
85V 12 (10.4) 2 (4.4) 0.353
88D/S 9 (7.8) 2 (4.4) 0.729
90M 48 (41.7) 12 (26.7) 0.102
* Fisher’s exact test, p < 0.05.
Table 7 – Patients with history of NFV intake and virological failure and the resistance pathway
Mutation Subtype B Subtype C Subtype F Subtype non-B
D30N (%) 6 (9.8) 1 (5) 0 (0) 1 (3.2)
L90M (%) 48 (78.7) 7 (35) 5 (45.5) 12 (38.7)
Silva, Telles, Cunha et al.
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Most of our knowledge about HIV is related to HIV-1 
subtype B, but the available data about other subtypes 
are increasing as viruses from developing countries have 
been studied.9,10 In Brazil, data from southeast and north 
regions are available.11 From the three states of south 
region, Paraná has less available information about 
HIV-1 clade prevalence.12
Subtype B was the predominant HIV-1 subtype in 
our sample, but other subtypes showed a significant fre-
quency. The three main subtypes in Brazil are B, C and F, 
with an increasing occurrence of recombinants BC and 
BF.4
It was previously reported that subtype non-B viruses 
were introduced later in Brazil than subtype B.13,14 In our 
work, for subtype B, patient’s oldest diagnosis was in 1983 
and for subtype C was 1991. The moment that the patients 
became aware of their HIV status cannot predict the length 
of infection, but we could suppose that non-B viruses were 
also introduced later than subtype B in Paraná.
USA and Europe reported an increasing number of cases 
of HIV-1 non-B cases, mainly in specifi c ethnical group and 
women and heterosexuals.15 Brazil is a multiracial country 
and the prevalence of Caucasians patients in south region 
is higher, as showed in all subtypes of viruses in our sample. 
But the higher prevalence of heterosexuals and woman in 
subtype non-B and MSM in subtype B followed the previ-
ous pattern reported by others.16 It was suggested that sub-
type C virus presents functional variations that favors its 
heterosexual transmission.17
Mutations 41L and 210W were more frequently found in 
virologic failure in subtype B. These are thymidine associated 
mutations and they occur after viral replication in the pres-
ence of thymidine analogues (stavudine and zidovudine).8 
When virologic failure occurs, there is a dichotomization of 
resistance pathway to 41L, 210W and 215Y or 67N, 70R and 
219Q18. In Brazil, initial ARV regimens included stavudine 
and zidovudine.19 The length of use of ARVs in our patients 
did not differ between subtypes. Others suggested that the 
pathway for resistance can be inﬂ uenced by subtype,20 with 
viruses from Brazil showing higher use of pathway 41L in 
subtype B than in subtype C.21,22 In Botswana, it was de-
scribed a distinct resistance pathway for subtype C after 
thymidine analogues use, presenting 67N, 70R and 215Y.20 
The resistance pathway used by the virus can predict future 
options of nucleoside analogues.
65R is a mutation that “in vitro” was described to occur 
more frequently in subtype C virus.23 This substitution oc-
curs after failing a regime that included TDF, ddI or ABC.8 
We observed only two viruses presenting 65R and both were 
subtype B. Authors from Brazil and other countries with 
higher prevalence of subtype C infection haven’t seen higher 
incidences of K65R in clinical samples.22,24,25 At least in Bra-
zil, with a frequent use of thymidine analogues in fi rst ARV 
regimen, the presence of thymidine associated mutations 
(TAMs) could avoid the appearance of K65R and that could 
be the reason of its lower prevalence.
We did not observe differences in frequency of NNRTIs 
RAMs in our patients. Subtype C viruses with NNRTI re-
sistance might develop 106A mutation instead of 106M, 
characteristic of subtype B viruses.26 The changes 106A and 
106M were rarely seen, and both occurred in one patient 
with subtype B and one patient with subtype C.
It was suggested that a Brazilian subtype C virus had 
specifi c amino acid signatures, not present in the world con-
sensus C.14 Authors showed higher frequency of changing of 
36 position in protease gene, and a higher prevalence of 63L 
mutation in Brazilian subtype B viruses. We observed higher 
frequency of 36 and 20 codon mutations in subtype C, as 
previously reported.27
90M was the preferential pathway of protease resist-
ance in patients with a failing regimen with nelfi navir. It is 
possible that the higher frequency of 36 position mutation 
observed in subtype non-B favors the 90M pathway.28 Also, 
because patients used another PI after NFV and the virus 
was not under selective pressure at time of genotyping, is 
possible that some patients had NFV related mutations that 
were archived but not showed in genotyping.
In conclusion, as other states from Southern region of 
Brazil, we observed in a group of patients from Paraná a 
signifi cant prevalence of non-B subtype HIV-1 viruses and 
they infect more frequently women and heterosexuals. Pa-
tients with different subtype viruses showed no other demo-
graphics of clinical signifi cant differences. Some preferences 
for resistance pathway and prevalence of mutations were de-
tected comparing subtype B and non-B viruses. The clinical 
impact of HIV-1 subtype diversity and difference frequency 
of mutations need more investigation.
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